BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma
NCT05341726
Recruiting
This study is an efficacy-implementation trial to: 1. evaluate systematically the efficacy of BREATHE in 200 Black adults receiving care at urban federally qualified health centers (FQHCs) for uncontrolled asthma; and 2. identify multi-level barriers and facilitators to the widespread adoption and implementation of BREATHE in FQHCs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Sun River Health, Beacon, New York +1 locations
Conditions: Asthma
Register for Updates
Forward Looking InfraRed Imaging and Severity Score in Complex Regional Pain Syndrome
NCT05852210
Recruiting
The goal of this interventional study is to explore the use of InfraRed (FLIR) imaging in determining pain intensity and severity in newly diagnosed complex regional pain syndrome patients. The main questions it aims to answer are: Question 1: Can Infrared (FLIR) imaging be used to determine the severity of CRPS in newly diagnosed patients? Question 2: Is there any correlation with the quantification of 'the Δ thermal index value' measured by FLIR imaging with pain intensity (NRS) in newly diag... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/24/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: CRPS (Complex Regional Pain Syndromes)
Register for Updates
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
NCT06097468
Recruiting
This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Oral Cavity Squamous Cell Carcinoma
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
NCT06706674
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
01/24/2025
Locations: Clinical Site, Little Rock, Arkansas +39 locations
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
NCT00349830
Recruiting
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms
Register for Updates
Undifferentiated Connective Tissue Disease Registry
NCT02234388
Recruiting
This registry has been established to gain a better understanding of the clinical and emotional presentations of patients with undifferentiated connective tissue disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Undifferentiated Connective Tissue Disease
Register for Updates
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
NCT04144023
Recruiting
This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma in situ. H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of increasing immune response and protecting against breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida +1 locations
Conditions: Breast Ductal Carcinoma In Situ
Register for Updates
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
NCT04634643
Recruiting
The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
01/24/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: NAFLD
Register for Updates
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277
Recruiting
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/24/2025
Locations: University Of Alabama, Birmingham, Alabama +178 locations
Conditions: Lupus Nephritis
Register for Updates
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
NCT05407129
Recruiting
Hospitals ineffectively examine the safety of their processes by relying on voluntary incident reporting (VIR) by clinical staff who are overworked and afraid to report. VIR captures only 1-10% of events, excludes patients and families, and underdetects events in vulnerable groups like patients with language barriers. Patients and families are vigilant partners in care who are adept at identifying errors and AEs. Failing to actively include patients and families in safety reporting and instead r... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/24/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Family Reported Errors and Adverse Events, Health Disparities, Family Safety Reporting, Patient Safety, Voluntary Incident Reporting, Quality Improvement
Register for Updates
Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy
NCT05905705
Recruiting
Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
01/24/2025
Locations: Washington University School of Medicine/Barnes-Jewish Hospital, Saint Louis, Missouri
Conditions: Treatment Resistant Depression
Register for Updates
Metabolic Effects of Perimenopause
NCT06098183
Recruiting
Starting in early-perimenopause, changes in systemic and tissue level metabolism result in an accelerated loss of muscle mass and an increase in body fat. Our preliminary work indicates that metabolic alterations, specifically a decrease in whole-body protein balance, increase in abdominal adiposity, and reduced metabolic flexibility during exercise is most evident in perimenopause. Exercise is a potent stimulator of skeletal muscle insulin sensitivity. High intensity interval training (HIIT) ha... Read More
Gender:
FEMALE
Ages:
Between 38 years and 60 years
Trial Updated:
01/24/2025
Locations: Applied Physiology Laboratory - University of North Carolina, Chapel Hill, North Carolina
Conditions: Perimenopausal Disorder
Register for Updates